Current Therapy of Cooley's Anemia: A Decade of Experience with Subcutaneous Desferrioxamine

Annals of the New York Academy of Sciences

Volumn 612, Issue 1, 1990, Pages 275-285

  GIARDINA, P J ^a   GRADY, R W ^a   EHLERS, K H ^a   BURSTEIN, S ^a   GRAZIANO, J H ^a   MARKENSON, A L ^a   HILGARTNER, M W ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; DEFEROXAMINE; DEFEROXAMINE MESYLATE;

CONFERENCE PAPER; ERYTHEMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NEUROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL; SPLENECTOMY; SUBCUTANEOUS DRUG ADMINISTRATION; THALASSEMIA MAJOR; TRANSFUSION;

BLOOD TRANSFUSION; DEFEROXAMINE; HUMAN; INFUSIONS, PARENTERAL; SPLENECTOMY; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; THALASSEMIA;

EID: 0025563805     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1990.tb24315.x     Document Type: Article

References (24)

1. Transfusion therapy in Cooley's Anemia: Growth and health as related to long range hemoglobin levels—A progress report
2. Prevention of bone malformations and cardiomegaly in Cooley's anemia by early hypertransfusion regimen
3. Hypertransfusion regimen in patients with Cooley's anemia
4. New approaches to the transfusion management of thalassemia
5. Iron absorption in the thalassemia syndromes and its inhibition by tea
6. Chelation therapy, transfusion requirement, and iron balance in young thalassemic patients
7. Current strategies in the management of Cooley's anemia
8. Filter columns for preparation of leukocyte‐poor blood for transfusion
9. The preparation of red cells depleted of leukocytes
10. Chelation therapy in β‐thalassemia major: III
11. Postsplenectomy infection in Cooley's anemia
12. Decreased natural killer activity in thalassemia major: A possible consequence of iron overload
13. Chelating agents in the diagnosis and treatment of iron overload in thalassemia
14. Chelation therapy in β‐thalassemia major: I
15. Continuous subcutaneous administration of deferoxamine in patients with iron overload
16. Feroxamine excretion in iron loaded man
17. Deferoxamine‐induced growth retardation in patients with thalassemia major
18. Improved growth in homozygous beta thalassemia with hypertransfusion and chelation therapy
19. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions
20. Vitamin C & iron
21. Rapid removal of excessive iron with daily high dose intravenous chelation therapy
22. Desferrioxamine use protects against heart disease and death from transfusional overload in thalassemia major
23. Improved survival in thalassemia major